Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...
Tori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight. But slimming down ...
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
CagriSema could still be a commercial success, though ... For one, semaglutide, the active ingredient in Wegovy, is being investigated in other areas with high unmet needs. Perhaps the best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback